Literature DB >> 1355801

Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV.

A Alberti1, G Morsica, L Chemello, D Cavalletto, F Noventa, P Pontisso, A Ruol.   

Abstract

There is controversy about clinical management of patients who persistently have antibodies to hepatitis C virus (anti-HCV) but who have no symptoms and signs of liver disease. We have taken liver biopsy samples from 23 such patients (16 of whom had normal alanine aminotransferase [ALT] values) to assess prevalence of liver disease and to see whether anti-HCV and HCV-RNA correlated with histological findings. 16 patients had histological evidence of chronic hepatitis, which was not predicted by serum ALT or by the pattern of specificity of anti-HCV. All 16 cases with hepatitis C viraemia (HCV-RNA detected by polymerase chain reaction), including 9 with normal ALT, had chronic hepatitis on biopsy (p less than 0.001), whereas 7 HCV-RNA-negative cases had normal liver histology. These findings indicate that serum HCV-RNA is a sensitive and specific marker of liver disease in anti-HCV-positive subjects, independent of ALT values, and challenge the idea of the existence of "true" healthy carriers of HCV.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355801     DOI: 10.1016/0140-6736(92)92234-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  48 in total

1.  Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology.

Authors:  A Grant; J Neuberger
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

2.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

3.  Hepatitis C: Recent advances.

Authors:  S D Shafran; J M Conly
Journal:  Can J Infect Dis       Date:  1993-07

4.  Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: results of a community-based study in north-western Sardinia.

Authors:  A Loviselli; A Oppo; F Velluzzi; F Atzeni; G L Mastinu; P Farci; G Orgiana; A Balestrieri; P L Cocco; S Mariotti
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

Review 5.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

6.  Managing chronic hepatitis C virus infection.

Authors:  J Y Lau; G L Davis
Journal:  BMJ       Date:  1993-02-20

7.  Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease.

Authors:  C M da Silva; F L David; M N Muscará; S S Sousa; J G Ferraz; G de Nucci; N C Polimeno; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

8.  Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus.

Authors:  J Hayashi; Y Kishihara; K Yamaji; E Yoshimura; M Ohmiya; Y Tani; H Ikematsu; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

9.  Incidence and morbidity of infection by hepatitis C virus in children with acute lymphoblastic leukaemia.

Authors:  S P Dibenedetto; R Ragusa; A Sciacca; A Di Cataldo; V Miraglia; S D'Amico; L Lo Nigro; A M Ippolito
Journal:  Eur J Pediatr       Date:  1994-04       Impact factor: 3.183

10.  Immunosuppressive therapy and hepatitis C virus infection: the clinical course of liver disease.

Authors:  W H Grotz; T H Peters; H J Schlayer; G Kirste; H Berthold; H Felten; P J Schollmeyer; J W Rasenack
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.